Your browser doesn't support javascript.
loading
Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.
Wang, Wei; Alvarado-Facundo, Esmeralda; Vassell, Russell; Collins, Limone; Colombo, Rhonda E; Ganesan, Anuradha; Geaney, Casey; Hrncir, David; Lalani, Tahaniyat; Markelz, Ana Elizabeth; Maves, Ryan C; McClenathan, Bruce; Mende, Katrin; Richard, Stephanie A; Schofield, Christina; Seshadri, Srihari; Spooner, Christina; Utz, Gregory C; Warkentien, Tyler E; Levine, Min; Coles, Christian L; Burgess, Timothy H; Eichelberger, Maryna; Weiss, Carol D.
Affiliation
  • Wang W; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Alvarado-Facundo E; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Vassell R; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Collins L; Defense Health Agency- Immunization Healthcare Division, Falls Church, Virginia, USA.
  • Colombo RE; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Ganesan A; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Geaney C; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • Hrncir D; Madigan Army Medical Center, Fort Lewis, Washington, USA.
  • Lalani T; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Markelz AE; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Maves RC; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • McClenathan B; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Mende K; Defense Health Agency- Immunization Healthcare Division Regional Office, Lackland AFB, Texas, USA.
  • Richard SA; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Schofield C; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • Seshadri S; Naval Medical Center, Portsmouth, Virginia.
  • Spooner C; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Utz GC; Division of Infectious Diseases, Naval Medical Center, San Diego, California, USA.
  • Warkentien TE; Defense Health Agency- Immunization Healthcare Division Regional Office, Ft. Bragg, North Carolina, USA.
  • Levine M; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Coles CL; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
  • Burgess TH; Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
  • Eichelberger M; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Weiss CD; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Clin Infect Dis ; 73(11): e4312-e4320, 2021 12 06.
Article in En | MEDLINE | ID: mdl-32898271
ABSTRACT

BACKGROUND:

Low vaccine effectiveness against A(H3N2) influenza in seasons with little antigenic drift has been attributed to substitutions in hemagglutinin (HA) acquired during vaccine virus propagation in eggs. Clinical trials comparing recombinant HA vaccine (rHA) and cell-derived inactivated influenza vaccine (IIV) to egg-derived IIVs provide opportunities to assess how egg-adaptive substitutions influence HA immunogenicity.

METHODS:

Neutralization titers in pre- and postimmunization sera from 133 adults immunized with 1 of 3 types of influenza vaccines in a randomized, open-label trial during the 2018-2019 influenza season were measured against egg- and cell-derived A/Singapore/INFIMH-16-0019/2016-like and circulating A(H3N2) influenza viruses using HA pseudoviruses.

RESULTS:

All vaccines elicited neutralizing antibodies to all H3 vaccine antigens, but the rHA vaccine elicited the highest titers and seroconversion rates against all strains tested. Egg- and cell-derived IIVs elicited responses similar to each other. Preimmunization titers against H3 HA pseudoviruses containing egg-adaptive substitutions T160K and L194P were high, but lower against H3 HA pseudoviruses without those substitutions. All vaccines boosted neutralization titers against HA pseudoviruses with egg-adaptive substitutions, but poorly neutralized wild-type 2019-2020 A/Kansas/14/2017 (H3N2) HA pseudoviruses.

CONCLUSION:

Egg- and cell-derived 2018-2019 season influenza vaccines elicited similar neutralization titers and response rates, indicating that the cell-derived vaccine did not improve immunogenicity against the A(H3N2) viruses. The higher responses after rHA vaccination may be due to its higher HA content. All vaccines boosted titers to HA with egg-adaptive substitutions, suggesting boosting from past antigens or better exposure of HA epitopes. Studies comparing immunogenicity and effectiveness of different influenza vaccines across many seasons are needed.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2021 Type: Article Affiliation country: United States